Opportunity for Oslo Cancer Cluster SMB´s: K Teams is a two week, intensive entrepreneurial training program in Boston and Cambridge.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 323 entries.
Entries by oslocancer
The draft SC1 Work Programme for 2016-17 has been pre-published at https://ec.europa.eu/programmes/horizon2020/en/draft-work-programmes-2016-17.
Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study .
Inven2 is the largest technology transfer company in the Nordic region and a leading actor within Life Science. They now have several therapies and methods to offer within immuno-oncology.
Oslo Cancer Cluster member BerGen BIO awarded Nordic Star at NLS Days2015.
Oslo Cancer Cluster member PCI Biotech has signed an agreement with an undisclosed top-10 large pharma company, with the aim to evaluate synergistic effects of the PCI technology with their therapeutic nucleic acid technology.
Oslo Cancer Cluster Innovation Park´s grand opening on August 24th became a very special day: More than 290 invited guests and a huge media turnout celebrated the initiators Jónas Einarsson and Kaare Norum for turning the radical idea of an oncology innovation park integrating a high school into reality.
PCI Biotech has activated Oslo University Hospital as a new clinical site in the phase I/II study of Amphinex in patients with inoperable bile duct cancer.
NLSDays September 9-10 at Stockholm Waterfront is the Nordic region’s premier life science event.
Oslo Cancer Cluster is hosting a Super Session at the Nordic Life Science Days in Stockholm. International thought leaders will discuss current game changing innovations and their impact on the industry in the years ahead.
The Norwegian Research Council and Norwegian Cancer Society are teaming up to make the results of medical and biotechnical research faster available for cancer patients.
The Norwegian Research Council recently announced four large investments in biomedical research on a total of 255 MNOK.
12 companies will have offices and lab in Oslo Cancer Cluster Incubator from August on. Bjørn Klem, General Manager of the Incubator, anticipates full house by January 2016.
On Thursday June 11 Oslo Cancer Cluster and the Cancer Society of Norway arranged a breakfast meeting on immunotherapy against cancer.
Monday August 24th is the official opening of the Oslo Cancer Cluster Innovation Park. The Prime Minister of Norway, Erna Solberg, will do the honours.
The companies contemplate a private placement of NOK 125–150 million to fund the combined business.
PhD student Marina Vietri and her co-workers in Harald Stenmark’s group at Centre for Cancer Biomedicine and Institute for Cancer Research have uncovered a new cellular mechanism that contributes to keep our genome intact.
Oslo Cancer Cluster member Vaccibody AS wil take part in SAPHIR, a 4 year collaborative research project that has succesfully raised 78 million NOK from the EU Horizon 2020 program.
Oslo Cancer Cluster member Vaccibody secures collaboration funding from the Research Council.
Oslo Cancer Cluster is one of the supporting organizations for this years Nordic Life Science Days in Stockholm: We host an Oncology Super Session and members get discount.
More than 10 Oslo Cancer Cluster members will be present at BIO2015 in Philadelphia in June.
For the 4th year on a row Oslo Cancer Cluster organizes International Cancer Cluster Showcase, ICCS at BIO.
Tilgang til nye kreftmedisiner var tema for seminar på Litteraturhuset 28. april. Du kan se hele møtet i opptak her.
PCI Biotech, a Norwegian cancer focused biopharmaceutical company, announced that it is initiating a pre-clinical research collaboration with RXi Pharmaceuticals (NASDAQ: RXII).
Nordic Nanovector ASA announces the successful completion of the bookbuilding period for its initial public offering, which was multiple times oversubscribed.
Oslo Cancer Cluster is one of the supporting organizations for this years Nodeic Life Science Days in Stockholm, as we were last year. This means that members of the cluster benefit from special rates on participation.
NICE makes evidence-based recommendations for healthcare, with the aim of improving treatment and reducing variations in care.
Mr. Øystein Soug, has been the CFO of the late-stage oncology biotech company Algeta ASA since 2008, building up the functions of Finance, IR, Compliance, IT and HR.
At this years Cancer Crosslinks we made short video interviews with presenters; Professor Paul Baas, Professor Nicholas Navin, Professor Bjørn Tore Gjertsen and professor Kimmo Porkka on their research and views on cancer treatments in the future.
The Norwegian Research Council granted BerGenBio, Lifandis and Smartfish – all Oslo Cancer Cluster member companies – funding from the BIA-programme now.
In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light.
Cancer researchers in Oslo are now using one of the world’s fastest computers to detect which parts of the genetic code may cause bowel and prostate cancer.
February 12, LMI, DNB Healthcare, AbbVie, Novartis and Pfizer hosts a one day seminar called A partnership for life in 2015 – How to develop a strong Norwegian biotechnology and health industry sector?
The technology allows for the development of new and more efficient vaccines as well as new versions of existing vaccines with a need for improved efficacy.
If you missed Cancer Crosslinks, or would like to watch some of the presentations again, here they are.
The funds raised through the share issue will be used to implement and further develop the company’s programme to document the effect of its first product; the therapeutic cancer vaccine UV1.
HORN International is developing the 2nd edition of the book European Biotechnology. Care to join? Oslo Cancer Cluster members receive special offer.
Cancer Crosslinks 2015 is on Thursday January 15. The meeting is fully booked. Follow it on live stream.
The governmental agency SIVA will support the Oslo Cancer Cluster Incubator with MNOK 15 over the next 10 years in order to develop cancer treatment from companies that spins out from strong cancer research.
Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces the conclusion of the Phase 2 program, and FDA clearance to prepare Phase 3 protocol for the clinical development of Cevira.
A recent analysis from the audit and advisory company EY is cautiously optimistic on behalf of startup companies in the Nordic Life Science industry – and points to possibilities within Oslo Cancer Cluster.
February 4th is World Cancer Day. Oslo Cancer Cluster will pay tribute to this day by arranging a breakfast meeting at Litteraturhuset together with LMI.
Oslo Cancer Cluster member BerGenBio AS announces that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors.
Real Karriere will take place February 12 2015. This is the meeting arena for industry and companies and the students within technolgy and natural sciences at the University of Oslo.
In 2012 there were just above 30,000 new cancer cases in Norway. The number of cases is increasing by 1-2 percent each year, so that more than 40,000 cases are expected in 2030.
BerGen Bio, Targovax and Ultimovacs are the winners of the Immuno-Oncology Call 2014. Each company will receive MNOK 0,4 from Innovation Norway.
Nordic Nanovector ASA and Affibody AB have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies for multiple myeloma.
Biotechgate welcomes the three Norwegian partners Innovation Norway, Oslo Cancer Cluster and Nansen Neuroscience Network.
Cancer Crosslinks 2015 will be held January 15th at The Institute for Cancer Research at the Norwegian Radium Hospital. The program features several renowned international speakers as well as Norwegian experts. Main theme is “Novel insights into tumor heterogeneity and clonal evolution: how to design treatment and follow-up strategies”. Program and registration form (close […]
Winners will be announced on Oslo Cancer Cluster`s Christmas Meeting December 1st.
Oslo Cancer Cluster members are invited to VIVO – career day at NTNU on January 22 2015.
The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO from January 12th, 2015.
Oslo Cancer Cluster member BerGenBio AS announces first patient dosed in its multi-centre Phase 1b trial of BGB324 in patients with acute myeloid leukaemia at Haukeland.
Oslo Cancer Cluster member Targovax AS has reached an important milestone in clinical trial phase I/II.
Almost 350 students at Oslo and Akershus University College of Applied Sciences was engaged in last weeks Innovation Camp where they were asked to come up with original ideas on how to communicate personalized cancer medicine.
Oslo Cancer Cluster would like to welcome our four new members on board: DNB Bank, Oslo and Akershus University College: Faculty of Health Sciences, Scandinavian Development Services and Prostataklinikken.
The Government of Norway launched their State Budget on October 8th. Overall, we are very pleased with the Government’s will for innovation and knowledge.
Oslo Cancer Cluster Incubator is delighted to inform that Bjørn Klem has been hired as General Manager. He will start January 1st 2015.
Professor Per Kogner and his research team at Karolinska Institute in Sweden have found that omega-3 fatty acids inhibit cancer growth.
Oslo’s cancer research community attracts international attention. Foreign companies engaged in the cancer field are flocking to Norway and Oslo to benefit from the city’s cancer research community.
Can the Healthcare Industry become a significant future growth platform? DNB invites all key personell on healthcare industry to an informal gatering.
Last year, a new vaccine technology aiming to manipulate our immune system and thereby combat cancer and HIV won Inven2’s idea competition. Do you have an idea that you want to further develop?
Yesterday Minister of Education Røe Isaksen and the Minister of Health Bent Høie visited Lytix Biopharma at the Department of Cell therapy at the Cancer Research Institute/Oslo University Hospital.
Oslo Cancer Cluster member BerGenBio AS has been granted a 1.6 million (NOK 16 million) Seeding Drug Discovery Award from the UK’s Wellcome Trust.
Oslo Cancer Cluster member Lytix Biopharma is one of three biotech companies awarded Nordic Stars 2014.
A very strong Scandinavian immunotherapy delegation is in the US September 15-19 to meet peers from some of the most prominent institutions “over there”.
Janssen wish to strengthen their medical affairs team in Norway and hereby we are seeking 2 field based Medical advisors to support our business in CNS and Oncology.
Karl Simpson from Liftstream, a company that provides recruitment services to the global life sciences sector, visited the Oslo Cancer Cluster this Summer.
Norwegian Healthcare actors have joined forces and launch the “Norwegian package” at next weeks Nordic Life Science Days/ECCP.
Oslo Cancer Cluster Incubator AS is looking for a General Manager. Oslo Cancer Cluster Incubator is a private company, 100% owned by Oslo Cancer Cluster SA.
Professor Ragnhild A. Lothe, Head of Dept of Cancer Prevention at Oslo University Hospital, will lead the new K.G.Jebsen Colorectal Cancer Research Centre that officially opened late August.
The Board of Nordic Nanovector is pleased to announce the appointment of Mr. Luigi Costa as new CEO.
PCI Biotech reports that the treatment evaluation of the second group in the ENHANCE study has been completed.
At least 17 Oslo cancer Cluster members will be represented in Stockholm September 7-9.
Oslo Cancer Cluster, in collaboration with Radiumhospitalets Legater, invite members and collaborators to the annual Oslo Cancer Cluster R&D Summer Meeting on Wednesday August 20th at the Auditorium , Institute of Cancer Research. Download program and register here The summer meeting will kick off the Oslo Cancer Cluster Innovation Park, and for the first time it […]
More than 170 people kicked-off the Oslo Cancer Cluster Innovation Park, opening in less than a year.
Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed.
In April 2014, Pharma TV interviewed Ketil Widerberg, General Manager of Oslo Cancer Cluster. Watch the interview and learn more about how Oslo Cancer Cluster works to develop new diagnostics and medication.
The HelseOmsorg21 strategy process was launched in 2013 by the Ministry of Health and Care services.
The program for the ECCP Oncology Track Sessions at NLS Days/ECCP in Stockolm is now ready. We are proud to present a strong program with international renowned speakers, representing the entire oncology value chain.
Researchers, clinicians and start-ups filled up the seminar room when Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 invited to a breakfast meeting on June 18th. The breakfast seminar had a special focus on protecting oncology innovations.
The Norwegian Research Council will grant NOK 850 million to industry innovation projects – the largest grant of its kind in history. Application deadline is October 15, 2014.
Oslo Cancer Cluster member Nordic Nanovector announce that the company has closed its pre-IPO private placement of NOK 250 million – 100 million more than anticipated.
Are you aiming for Asian markets? Innovation Norway presents the Tech Incubator Program – TINC TINC in Silicon Valley has created great opportunities for Norwegian tech entrepreneurs and has been fundamental in Innovation Norway’s efforts towards global entrepreneurs. These days the concept is extended to Asian markets with Singapore as the epicenter. Please find more […]
Targovax AS is registered on the NOTC-list from June 16th, 2014, with ticker code TRVX. The company has issued 9 429 404 shares, each at par value NOK 0.10. All shares are registered in VPS with ISIN code NO 001 0689326. Based on the most recent capital increase, June 4th, 2014, where the shares were […]
Oslo Cancer Cluster member Nordic Nanovector`s lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC). Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as […]
MBA students from University of Cambridge did a benchmarking of international oncology clusters this spring on behalf of the Oslo Cancer Cluster. Please download an excerpt of the report here. Key findings; • Norway has a high number of oncology publications per capita • The entrepreneurial culture in Norway represents untapped commercial potential • There […]
Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to […]
The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell novel vaccines for the poultry market using the Vaccibody platform technology. Under the agreement, Phibro and […]
Lytix Bioharma presents data at ASCO from the first LTX-315 clinical trial. Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics – Immunotherapy Poster Session’. The poster […]
Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 kindly invite researchers, clinicians and start-ups to learn more about securing IPR in oncology projects.
Smartfish is a Norwegian company developing synergistic omega 3 based pharmaconutrition products. Smartfih is now studying the effect of their phamaconutrition on the immune system, and would like to get in contact with Norwegian collaborators. Smartfish joined the Oslo Cancer Cluster in 2014 and currently have two products on the market that have been clinically […]
The Norwegian Cancer Society (NCS) have established an investment fund for Norwegian oncology companies, and their first investment are in Oslo Cancer Cluster Member Vaccibody.
Present your oncology innovation to the global life science industry at the largest partnering conference in the Nordics – Nordic Life Science Days featuring the 6th European Cancer Cluster Partnering (ECCP).
The PCI Biotech stock went straight up on the Norwegian Stock Exchange after successful results from the first dose cohort in the phase I/II study in patients with bile duct cancer. No safety concerns were observed at this dose level.
The liberal party Venstre have proposed the implementation of the “Helsemyggordningen,” a financial mechanism for stimulation of health innovation, for the Norwegian Parliament. The proposal have been designated to the The Standing Committee on Finance and Economic Affairs in the Parliament.
The Radium Hospital Foundation (Radiumhospitalets Legater) will support the Oslo Cancer Clusters R&D Network Meetings 2014, and collaborate closely with the cluster on developing these meetings.
The Fridtjof Nansen prize for excellent research in science and medicine 2014 is awarded to Centre for Cancer Biomedicine’s Kirsten Sandvig for her groundbreaking work within biochemistry and cell biology.
Cancer Crosslinks 2014, January 23, was the 6th edition of this annual oncology conference bringing together hematologists, oncologists and the industry in Norway.
BerGenBio AS, an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013.
Contact Team >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.